Abstract:<p></p><p>Phosphodiesterases(PDEs) are vital in signal transduction, specificallyby hydrolyzing cAMP and cGMP. Within the PDE family, PDE10A is notablefor its prominence in the striatum and its regulatory function overneurotransmitters in medium-spiny neurons. Given the dopamine deficiencyin Parkinson’s disease (PD) that affects striatal pathways,PDE10A inhibitors could offer therapeutic benefits by modulating D1and D2 receptor signaling. This study was motivated by the successfulhistory of quinazoline/quinazoline scaffolds in the inhibition ofPDE10A. This study involved detailed in silico evaluationsthrough docking followed by pharmacological, pharmacophoric, and pharmacokineticanalyses, prioritizing central nervous system (CNS)-active drug criteria.Seven cyclic peptides, those featuring the quinazoline/quinazolinemoiety at both termini, exhibited notably enhanced docking scorescompared to those of the remaining alkaloids within the screened library.We identified 7 quinolines and 1 quinazoline including Lepadin G,Aspernigerin, CJ-13536, Aurachin A, 2-Undecyl-4(1H)-quinolone, Huajiaosimuline 3-Prenyl-4-prenyloxyquinolin-2-one,and Isaindigotone that followed the standard CNS active drug criteria.The dominant quinoline ring in our study and its related quinazolinewere central to our evaluations; therefore, the pharmacophoric featuresof these scaffolds were highlighted. The top alkaloids met all CNS-activedrug properties; while nonmutagenic and without PAINS alerts, manyindicated potential hepatotoxicity. Among the compounds, Huajiaosimulinewas particularly significant due to its alignment with lead-likenessand CNS-active criteria. Aspernigerin demonstrated its affinity fornumerous dopamine receptors, which signifies its potential to alterdopaminergic neurotransmission that is directly related to PD. Interestingly,the majority of these alkaloids had biological targets primarily associatedwith G protein-coupled receptors, critical in PD pathophysiology.They exhibit superior excretion parameters and toxicity end-pointscompared to the standard. Notably, selected alkaloids demonstratedstability in the binding pocket of PDE10A according to the moleculardynamic simulation results. Our findings emphasize the potential ofthese alkaloids as PDE10A inhibitors. Further experimental studiesmay be necessary to confirm their actual potency in inhibiting PDE10Abefore exploring their therapeutic potential in PD.</p>

Identification and Optimization of Nitrophenolic Analogues As Dopamine Metabolic Enzyme Inhibitors for the Treatment of Parkinson’s Disease

Optimization of N-Phenylpropenoyl-l-amino Acids As Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease.

Optimization of N -Phenylpropenoyl- l -amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease

Discovery of Novel Benzimidazole Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors for Parkinson's Disease Treatment

Novel 1-(Prop-2-yn-1-ylamino)-2,3-dihydro-1h-indene-4-thiol Derivatives As Potent Selective Human Monoamine Oxidase B Inhibitors: Design, SAR Development, and Biological Evaluation.

Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor

Enhancing Monoamine Oxidase B Inhibitory Activity Via Chiral Fluorination: Structure-activity Relationship, Biological Evaluation, and Molecular Docking Study.

Novel flavonoid 1,3,4-oxadiazole derivatives ameliorate MPTP-induced Parkinson's disease via Nrf2/NF-κB signaling pathway

Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.

Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis

Synthesis and biological evaluation of clovamide analogues with catechol functionality as potent Parkinson's disease agents in vitro and in vivo.

Design, synthesis and evaluation of monoketene compounds as novel potential Parkinson's disease agents by suppressing ER stress via AKT

Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson’s disease

Identification and Optimization of Piperine Analogues As Neuroprotective Agents for the Treatment of Parkinson's Disease Via the Activation of Nrf2/keap1 Pathway.

6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatment

Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson’s disease via the activation of Nrf2/keap1 pathway

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson’s Disease through a Computational Approach

DFT and QSAR study of Catechol-O-methyltransferase (COMT) as inhibitors for Parkinson's disease treatment

Discovery and characterization of naturally occurring potent inhibitors of catechol- O -methyltransferase from herbal medicines

Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease